Atriance, also known by its active ingredient nelarabine, is a chemotherapy medication primarily used in the treatment of certain types of leukemia and lymphoma, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) when other treatments have not been effective. It is classified as a purine nucleoside analog, which works by interfering with the DNA synthesis of cancer cells, thereby slowing or stopping their growth and proliferation. Atriance is administered intravenously, and its use is associated with a range of potential side effects, which can vary in severity. Due to its potent activity and the risk of serious side effects, Atriance's administration and dosage are carefully managed by healthcare professionals specializing in oncology.